Crinetics Pharmaceuticals, Inc. (CRNX) News

Crinetics Pharmaceuticals, Inc. (CRNX): $20.55

-0.04 (-0.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CRNX News Items

CRNX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CRNX News Highlights

  • For CRNX, its 30 day story count is now at 2.
  • Over the past 8 days, the trend for CRNX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about CRNX are RARE.

Latest CRNX News From Around the Web

Below are the latest news stories about Crinetics Pharmaceuticals Inc that investors may wish to consider to help them evaluate CRNX as an investment opportunity.

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in a fireside chat at the annual SVB Leerink Global Healthcare Conference, which is being held in a virtual format February 14-18, 2022. Details of the presentation are as fol

Yahoo | February 9, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on February 1, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 135,000 shares of its common stock to seven new non-exe

Yahoo | February 1, 2022

What Kind Of Investors Own Most Of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)?

A look at the shareholders of Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) can tell us which group is most powerful...

Yahoo | January 24, 2022

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference

- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 - Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with neuroendocrine tumors expected in 2022 - - Initiation of IND-enabling studies for parathyroid receptor type-1 antagonist expected in 2022 - SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D. , founder & CEO of Crinetics, will provide a company update at the 40 th annual J.P. Morgan Healthcare Conference today, Wednesday, January 12 th at 4:...

Benzinga | January 12, 2022

Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

Yahoo | December 28, 2021

Zacks Investment Research Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy

Zacks Investment Research upgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a hold rating to a buy rating in a report issued on Tuesday morning, Zacks.com reports. The firm currently has $28.00 price objective on the stock. According to Zacks, Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and [] The post Zacks Investment Research Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy appeared first on ETF Daily News .

ETF Daily News | December 22, 2021

Zacks Investment Research Downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Hold

Crinetics Pharmaceuticals (NASDAQ:CRNX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare []

Transcript Daily | December 19, 2021

Brokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Target Price at $36.80

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) has earned an average rating of Buy from the seven ratings firms that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year []

Transcript Daily | December 17, 2021

Zacks Investment Research Lowers Crinetics Pharmaceuticals (NASDAQ:CRNX) to Hold

Crinetics Pharmaceuticals (NASDAQ:CRNX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases []

Dakota Financial News | December 12, 2021

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 9%

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) was down 9% during mid-day trading on Thursday . The stock traded as low as $24.70 and last traded at $24.86. Approximately 11,130 shares traded hands during trading, a decline of 94% from the average daily volume of 190,346 shares. The stock had previously closed at $27.32. Several analysts have issued []

Transcript Daily | December 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5454 seconds.